Nature Reviews Disease Primers, volume 10, issue 1, publication number 39
Trigeminal neuralgia
Sait Ashina
1, 2, 3
,
Carrie E. Robertson
4
,
Anan Srikiatkhachorn
5
,
Giulia Di Stefano
6
,
Anne Donnet
7
,
M. Hodaie
8
,
Mark Obermann
9, 10
,
Marcela Romero-Reyes
11
,
Young Seok Park
12, 13
,
Giorgio Cruccu
6
,
Lars Bendtsen
4, 14
7
Department of Evaluation and Treatment of Pain, FHU INOVPAIN, Centre Hospitalier Universitaire de Marseille, Hopital de la Timone, Assistance Publique-Hopitaux de Marseille, Marseille, France
9
Department of Neurology, Hospital Weser-Egge, Hoexter, Germany
Publication type: Journal Article
Publication date: 2024-05-30
Journal:
Nature Reviews Disease Primers
scimago Q1
SJR: 10.215
CiteScore: 76.7
Impact factor: 76.9
ISSN: 2056676X
Abstract
Trigeminal neuralgia (TN) is a facial pain disorder characterized by intense and paroxysmal pain that profoundly affects quality of life and presents complex challenges in diagnosis and treatment. TN can be categorized as classical, secondary and idiopathic. Epidemiological studies show variable incidence rates and an increased prevalence in women and in the elderly, with familial cases suggesting genetic factors. The pathophysiology of TN is multifactorial and involves genetic predisposition, anatomical changes, and neurophysiological factors, leading to hyperexcitable neuronal states, central sensitization and widespread neural plasticity changes. Neurovascular compression of the trigeminal root, which undergoes major morphological changes, and focal demyelination of primary trigeminal afferents are key aetiological factors in TN. Structural and functional brain imaging studies in patients with TN demonstrated abnormalities in brain regions responsible for pain modulation and emotional processing of pain. Treatment of TN involves a multifaceted approach that considers patient-specific factors, including the type of TN, with initial pharmacotherapy followed by surgical options if necessary. First-line pharmacological treatments include carbamazepine and oxcarbazepine. Surgical interventions, including microvascular decompression and percutaneous neuroablative procedures, can be considered at an early stage if pharmacotherapy is not sufficient for pain control or has intolerable adverse effects or contraindications. In this Primer, Ashina et al. discuss the epidemiology, pathophysiology, diagnosis, management and quality of life of patients with trigeminal neuralgia, a chronic neuropathic facial pain disorder involving one or more branches of the trigeminal nerve that causes intense paroxysms of electric shock-like pain.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.